[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100516777":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":35,"locations":41,"responsibleParty":151,"collaborators":10,"id":153,"slug":154,"hasResults":155,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":155,"sex":161,"minAge":162,"maxAge":10,"enrollmentInfo":163,"targetDuration":10,"studyType":166,"phases":10,"briefSummary":167,"conditions":168,"keywords":170,"overallStatus":44,"whyStopped":10,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":180},{"fullName":5,"class":6},"CSL Behring","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"HEMGENIX",null,"Patients with hemophilia B treated with HEMGENIX in countries where HEMGENIX is approved for commercial use.",[13],"Genetic: HEMGENIX",{"label":15,"type":10,"description":16,"interventionNames":17},"FIX Prophylaxis","Patients with hemophilia B on FIX prophylaxis and enrolled in American Thrombosis and Hemostasis Network (ATHN) Transcends (A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment in People with Non-Neoplastic Hematologic Disorders) Hemophilia Cohort, or a similar registry.",[18],"Biological: Factor IX (FIX)",[20,26],{"type":21,"name":9,"description":22,"armGroupLabels":23,"otherNames":24},"GENETIC","HEMGENIX is a gene therapy medicinal product that aims to deliver a factor IX (FIX) gene expression cassette to the liver of patients with hemophilia B.",[9],[25],"Etranacogene dezaparvovec",{"type":27,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"BIOLOGICAL","Factor IX (FIX)","FIX prophylaxis therapy",[15],[32],{"name":33,"affiliation":5,"role":34},"Global Program Director","STUDY_DIRECTOR",[36],{"name":37,"role":38,"phone":39,"phoneExt":10,"email":40},"Trial Registration Coordinator","CONTACT","+1 610-878-4697","clinicaltrials@cslbehring.com",[42,56,66,71,81,89,97,107,115,123,131,141],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"countryCode":49,"cosmosGeoPoint":50,"geoPoint":55,"contacts":10},"American Thrombosis and Hemostasis Network","RECRUITING","Rochester","New York","14604","United States","US",{"type":51,"coordinates":52},"Point",[53,54],-77.61556,43.15478,{"lat":54,"lon":53},{"facility":57,"status":44,"city":58,"state":10,"zip":10,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":65,"contacts":10},"Medical University Vienna","Vienna","Austria","AT",{"type":51,"coordinates":62},[63,64],16.37208,48.20849,{"lat":64,"lon":63},{"facility":67,"status":44,"city":68,"state":10,"zip":10,"country":69,"countryCode":70,"cosmosGeoPoint":10,"geoPoint":10,"contacts":10},"Aarhus Universitetshospital","Århus N","Denmark","DK",{"facility":72,"status":44,"city":73,"state":10,"zip":10,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":80,"contacts":10},"Centre Hospitalier Universitaire de Brest \u002F CHU Morvan","Brest","France","FR",{"type":51,"coordinates":77},[78,79],-4.48628,48.39029,{"lat":79,"lon":78},{"facility":82,"status":44,"city":83,"state":10,"zip":10,"country":74,"countryCode":75,"cosmosGeoPoint":84,"geoPoint":88,"contacts":10},"Centre Régional de Traitement de l'Hémophilie","Nantes",{"type":51,"coordinates":85},[86,87],-1.55336,47.21725,{"lat":87,"lon":86},{"facility":90,"status":44,"city":91,"state":10,"zip":10,"country":74,"countryCode":75,"cosmosGeoPoint":92,"geoPoint":96,"contacts":10},"CHU Nancy - Hôpital Brabois","Vandœuvre-lès-Nancy",{"type":51,"coordinates":93},[94,95],6.17114,48.66115,{"lat":95,"lon":94},{"facility":98,"status":44,"city":99,"state":10,"zip":10,"country":100,"countryCode":101,"cosmosGeoPoint":102,"geoPoint":106,"contacts":10},"Klinik für Angiologie\u002F Hämostaseologie","Berlin","Germany","DE",{"type":51,"coordinates":103},[104,105],13.41053,52.52437,{"lat":105,"lon":104},{"facility":108,"status":44,"city":109,"state":10,"zip":10,"country":100,"countryCode":101,"cosmosGeoPoint":110,"geoPoint":114,"contacts":10},"University of Clinic Bonn","Bonn",{"type":51,"coordinates":111},[112,113],7.09549,50.73438,{"lat":113,"lon":112},{"facility":116,"status":44,"city":117,"state":10,"zip":10,"country":100,"countryCode":101,"cosmosGeoPoint":118,"geoPoint":122,"contacts":10},"Klinikum der Johann-Wolfgang Goethe Universitaet","Frankfurt",{"type":51,"coordinates":119},[120,121],10.53333,49.68333,{"lat":121,"lon":120},{"facility":124,"status":44,"city":125,"state":10,"zip":10,"country":100,"countryCode":101,"cosmosGeoPoint":126,"geoPoint":130,"contacts":10},"Hannover Medical School","Hanover",{"type":51,"coordinates":127},[128,129],9.73322,52.37052,{"lat":129,"lon":128},{"facility":132,"status":44,"city":133,"state":10,"zip":10,"country":134,"countryCode":135,"cosmosGeoPoint":136,"geoPoint":140,"contacts":10},"Hospital Alvaro Cunqueiro Dr. Manuel Rodriquez-Lopez","Vigo","Spain","ES",{"type":51,"coordinates":137},[138,139],-8.72264,42.23282,{"lat":139,"lon":138},{"facility":142,"status":44,"city":143,"state":10,"zip":10,"country":144,"countryCode":145,"cosmosGeoPoint":146,"geoPoint":150,"contacts":10},"University Hospital Bern Inselspital","Bern","Switzerland","CH",{"type":51,"coordinates":147},[148,149],7.44744,46.94809,{"lat":149,"lon":148},{"type":152,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100516777","an-observational-cohort-study-to-characterize-the-effectiveness-and-safety-of-hemgenix-in-patients-with-hemophilia-b-100516777",false,"NCT06008938","An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B","An Observational Post-authorization Long-term Follow-up Study to Characterize the Effectiveness and Safety of HEMGENIX® (Etranacogene Dezaparvovec) in Patients With Hemophilia B","IX-TEND 4001","Inclusion Criteria:\n\n* HEMGENIX Cohort:\n* \\- Treatment with commercial HEMGENIX.\n* \\- Have provided signed written informed consent within 3 months before or within 6 months after HEMGENIX treatment, or within 6 months of when the study is initiated at the participating site.\n* FIX Prophylaxis Cohort:\n* \\- Adult patients (≥ 18 years) with hemophilia B who have consented and enrolled in ATHN Transcends Hemophilia Cohort (or a similar registry) and are receiving FIX prophylaxis therapy.\n\nExclusion Criteria:\n\n* HEMGENIX Cohort:\n* \\- The patient population that will be observed in this study must not have been treated with etranacogene dezaparvovec in a clinical trial.","ALL","18 Years",{"count":164,"type":165},500,"ESTIMATED","OBSERVATIONAL","This observational, post-authorization, long-term follow-up study aims to investigate the short and long-term effectiveness and safety of HEMGENIX in patients with hemophilia B. The study will also include a cohort of patients with hemophilia B treated with FIX prophylaxis to enable interpretation of relevant efficacy and safety findings of HEMGENIX.",[169],"Hemophilia B",[169,9],"2026-02-18",{"date":173,"type":174},"2026-02-19","ACTUAL",{"date":176,"type":174},"2023-06-15",{"date":178,"type":165},"2043-08-01",{"name":5,"class":6},12]